Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Royaltee's uuuhhhmmmm love the smell

CUPERTINO, Calif. – October 5, 2009 – Alliacense announced today a wave of new MMP™ Portfolio licensees less than three weeks after the USPTO announced it's decision to affirm the validity of US’336, the most widely recognized patent in the MMP Portfolio. The new licensees include Harman International, TPV Technology, and Textron Inc., and will result in both upfront and future payments, as the increasing rates of the MMP Licensing Program has made onetime, lump-sum licenses too expensive for some companies.

There it is in plain english from the Alliacense announcement "future payments". Notice the s after payment this means more than one. I would call this reocurring payments or reocuuring royalties. PTSC said a while back that this type of payment plan was being offered to companies but that no company had yet chose that option for payment. Looks like now some have by the Alliacense announcement and I would expect more companies to choose this form of payment going forward to spread out the cost.

Steve

Share
New Message
Please login to post a reply